356 related articles for article (PubMed ID: 32020470)
1. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
2. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Toms SA; Kim CY; Nicholas G; Ram Z
J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
5. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
7. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
8. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W
J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259
[TBL] [Abstract][Full Text] [Related]
10. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
[TBL] [Abstract][Full Text] [Related]
11. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
12. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
Front Oncol; 2020; 10():411. PubMed ID: 32373508
[No Abstract] [Full Text] [Related]
14. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
15. Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center.
Chen C; Xu H; Song K; Zhang Y; Zhang J; Wang Y; Sheng X; Chen L; Qin Z
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233722
[TBL] [Abstract][Full Text] [Related]
16. Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Guzauskas GF; Salzberg M; Wang BC
CNS Oncol; 2018 Jul; 7(3):CNS23. PubMed ID: 30124334
[TBL] [Abstract][Full Text] [Related]
17. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
18. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
Miller R; Song A; Ali A; Niazi M; Bar-Ad V; Martinez N; Glass J; Alnahhas I; Andrews D; Judy K; Evans J; Farrell C; Werner-Wasik M; Chervoneva I; Ly M; Palmer J; Liu H; Shi W
Front Oncol; 2022; 12():896246. PubMed ID: 35574391
[TBL] [Abstract][Full Text] [Related]
19. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
20. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
